Table 4 Characteristics at ICU admission of patients who received remifentanil for 96 hours or more before discontinuation
From: Remifentanil discontinuation and subsequent intensive care unit-acquired infection: a cohort study
Characteristic | ICU-acquired infection n = 153 | No ICU-acquired infection n = 113 | P value |
|---|---|---|---|
Age | 61 ± 14 | 53 ± 16 | < 0.001 |
Male gender | 100 (65) | 78 (69) | 0.620 |
SAPS II | 51 ± 16 | 47 ± 19 | 0.035 |
LOD score | 5.5 ± 3.4 | 5.2 ± 3.3 | 0.435 |
McCabe score | 0.028 | ||
Nonfatal underlying disease | 67 (43) | 67 (59) | |
Ultimately fatal underlying disease | 69 (45) | 40 (35) | |
Rapidly fatal underlying disease | 17 (11) | 6 (5) | |
Glasgow coma score | 10 ± 2 | 11 ± 2 | 0.651 |
Admission category | > 0.999 | ||
Medical | 110 (71) | 82 (72) | |
Surgical | 43 (28) | 31 (27) | |
Transfer from other wards | 107 (69) | 63 (55) | < 0.024* |
Comorbidities | |||
COPD | 42 (27) | 38 (33) | 0.342 |
Chronic heart failure | 37 (24) | 20 (17) | 0.262 |
Immunosuppression | 34 (22) | 20 (17) | 0.452 |
Diabetes mellitus | 24 (15) | 30 (26) | 0.043† |
Infection | 103 (67) | 73 (64) | 0.740 |
Prior antibiotic treatment | 76 (49) | 51 (45) | 0.543 |
Length of prior hospital stay, days (interquartile range) | 1 (0 to 2) | 1 (0 to 5) | 0.737 |